Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Eli Lilly’s Global CEO David Ricks revealed that the pharma giant might manufacture its weight-loss blockbuster, Mounjaro, in ...

Ozempic, the Danish pharma giant Novo Nordisk's anti-diabetic drug, has had everyone's attention over the past year. The ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India, marking its entry into a rapidly growing market.

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

My DCF analysis suggests that Eli Lilly's stock is 60% undervalued. Defensive healthcare stocks like Eli Lilly are favorable in the current uncertain macroenvironment, driven by tariff concerns ...

Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. Eli Lilly's Current ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...

Cristina Arias / Cover / Getty Images Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly ... and Wegovy and Lilly's Mounjaro and Zepbound.

Eli Lilly stock has advanced ... I'm talking about weight loss drugs. Lilly makes tirzepatide, commercialized under the name Zepbound for weight loss and Mounjaro for type 2 diabetes.

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive — and covered an exclusive trip for leaders to attend last summer’s ...